MaxCyte signs platform licence with biotech firm Intima
Maxcyte (DI)
315.16p
09:24 08/05/24
Cell engineering platform technology company MaxCyte announced the signing of a strategic platform licence (SPL) with Intima Bioscience on Tuesday.
FTSE AIM 100
3,748.43
13:45 08/05/24
FTSE AIM All-Share
777.13
13:45 08/05/24
The AIM-traded firm described Intima as a clinical-stage biotechnology company developing genetically-engineered cell therapies for solid tumour cancer, adding that it was joining a group of 15 other cell therapy companies that had partnered with MaxCyte.
Under the agreement, Intima would obtain non-exclusive clinical and commercial rights to use MaxCyte's ‘Flow Electroporation’ technology and ‘ExPERT’ platform.
In return, MaxCyte would be entitled to receive platform licensing fees and programme-related milestone payments.
Intima was currently running a phase 1 and 2 clinical study of its lead checkpoint cell therapy candidate, which was targeting the immune checkpoint ‘CISH’ in patients with gastrointestinal and colon cancers.
“We are proud to be working with Intima, a cell therapy leader leveraging the unique power of genetically engineered tumour infiltrating lymphocytes (eTIL),” said president and chief executive officer Doug Doerfler.
“This relationship represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in additional novel cell types.”
At 1209 GMT, shares in MaxCyte were up 6.7% in London, at 492.94p.